Autonomix Medical FY2024 net loss $15.4M; cash $8.6M; topline data from first 5 patients expected June

Autonomix Medical, Inc.

Net loss $15.4M vs $2.0M prior year, including $8.0M non-cash warrant loss; G&A $5.2M, R&D $2.2M.
Cash $8.6M at March 31, 2024; expects runway into Q1 2025 after $9.8M net IPO proceeds.
IPO raised $11.2M gross ($9.8M net) via 2,234,222 shares at $5.00 each.
PoC human clinical study for pancreatic cancer pain ongoing; topline data from first 5 patients expected in June 2024.
Preclinical study showed statistically significant reduction in metastases and tumor mass with targeted nerve ablation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.